| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Abiraterone and increased survival in metastatic prostate cancer.
|
N Engl J Med
|
2011
|
27.58
|
|
2
|
Increased survival with enzalutamide in prostate cancer after chemotherapy.
|
N Engl J Med
|
2012
|
20.79
|
|
3
|
Abiraterone in metastatic prostate cancer without previous chemotherapy.
|
N Engl J Med
|
2012
|
15.69
|
|
4
|
Enzalutamide in metastatic prostate cancer before chemotherapy.
|
N Engl J Med
|
2014
|
11.05
|
|
5
|
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.
|
Lancet
|
2011
|
8.81
|
|
6
|
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
|
Lancet Oncol
|
2013
|
4.91
|
|
7
|
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
|
Eur J Cancer
|
2012
|
4.29
|
|
8
|
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
|
Lancet Oncol
|
2012
|
3.82
|
|
9
|
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
|
Lancet Oncol
|
2013
|
3.45
|
|
10
|
Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer.
|
Eur Urol
|
2008
|
3.06
|
|
11
|
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.
|
J Clin Oncol
|
2013
|
2.52
|
|
12
|
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.
|
Eur Urol
|
2007
|
2.21
|
|
13
|
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure.
|
J Bone Miner Res
|
2010
|
2.15
|
|
14
|
EAU guidelines on testicular cancer: 2011 update.
|
Eur Urol
|
2011
|
1.96
|
|
15
|
Active surveillance is the preferred approach to clinical stage I testicular cancer.
|
J Clin Oncol
|
2013
|
1.81
|
|
16
|
Targeting continued androgen receptor signaling in prostate cancer.
|
Clin Cancer Res
|
2011
|
1.80
|
|
17
|
Carcinoma of unknown primary (CUP).
|
Crit Rev Oncol Hematol
|
2008
|
1.65
|
|
18
|
Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.
|
J Urol
|
2012
|
1.61
|
|
19
|
Cancer of unknown primary (CUP).
|
Crit Rev Oncol Hematol
|
2005
|
1.53
|
|
20
|
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
|
Lancet Oncol
|
2013
|
1.51
|
|
21
|
Enzalutamide in European and North American men participating in the AFFIRM trial.
|
BJU Int
|
2014
|
1.43
|
|
22
|
Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site.
|
J Clin Oncol
|
2002
|
1.40
|
|
23
|
Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI.
|
Onkologie
|
2012
|
1.39
|
|
24
|
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.
|
Eur Urol
|
2007
|
1.37
|
|
25
|
Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).
|
J Clin Oncol
|
2003
|
1.30
|
|
26
|
[Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site].
|
Bull Cancer
|
2002
|
1.24
|
|
27
|
Sequential therapy in renal cell carcinoma.
|
Cancer
|
2009
|
1.18
|
|
28
|
Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.
|
Cancer
|
2012
|
1.16
|
|
29
|
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.
|
Urology
|
2011
|
1.15
|
|
30
|
Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone.
|
Clin Cancer Res
|
2012
|
1.13
|
|
31
|
Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.
|
Cancer
|
2013
|
1.13
|
|
32
|
Long-term results of brachytherapy for carcinoma of the penis confined to the glans (N- or NX).
|
Int J Radiat Oncol Biol Phys
|
2009
|
1.07
|
|
33
|
Controversies in the management of clinical stage I testis cancer.
|
J Clin Oncol
|
2006
|
1.05
|
|
34
|
Chemotherapy in patients with teratoma with malignant transformation.
|
Eur Urol
|
2006
|
1.03
|
|
35
|
Treatment for patients with unknown primary cancer and favorable prognostic factors.
|
Semin Oncol
|
2009
|
1.03
|
|
36
|
Advanced seminoma--treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients.
|
Cancer
|
2003
|
1.00
|
|
37
|
Carcinomas of an unknown primary origin--diagnosis and treatment.
|
Nat Rev Clin Oncol
|
2011
|
1.00
|
|
38
|
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.
|
Eur J Cancer
|
2013
|
0.98
|
|
39
|
New and emerging therapies for bone metastases in genitourinary cancers.
|
Eur Urol
|
2012
|
0.95
|
|
40
|
Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
|
J Clin Oncol
|
2008
|
0.95
|
|
41
|
The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer.
|
Eur J Cancer
|
2010
|
0.94
|
|
42
|
Intra-abdominal desmoplastic small round cell tumors: CT findings and clinicopathological correlations in 13 cases.
|
Eur J Radiol
|
2005
|
0.93
|
|
43
|
STEAP, a prostate tumor antigen, is a target of human CD8+ T cells.
|
Cancer Immunol Immunother
|
2006
|
0.93
|
|
44
|
Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach.
|
Crit Rev Oncol Hematol
|
2008
|
0.93
|
|
45
|
Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
|
Eur J Cancer
|
2013
|
0.90
|
|
46
|
A 10-year clinical experience with intermittent hormonal therapy for prostate cancer.
|
Eur Urol
|
2003
|
0.87
|
|
47
|
Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer.
|
Exp Cell Res
|
2010
|
0.86
|
|
48
|
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study.
|
Invest New Drugs
|
2014
|
0.86
|
|
49
|
Patient preference for either the EORTC QLQ-C30 or the FACIT Quality Of Life (QOL) measures: a study performed in patients suffering from carcinoma of an unknown primary site (CUP).
|
Eur J Cancer
|
2004
|
0.86
|
|
50
|
Bone targeted therapies in metastatic castration-resistant prostate cancer.
|
Cancer J
|
2013
|
0.85
|
|
51
|
Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen.
|
Eur J Cancer
|
2012
|
0.85
|
|
52
|
The use of estramustine phosphate in the modern management of advanced prostate cancer.
|
BJU Int
|
2011
|
0.85
|
|
53
|
Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis.
|
J Thorac Cardiovasc Surg
|
2009
|
0.84
|
|
54
|
Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.
|
Oncotarget
|
2014
|
0.83
|
|
55
|
The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer.
|
Neoplasia
|
2012
|
0.83
|
|
56
|
Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.
|
Cancer Immunol Immunother
|
2015
|
0.82
|
|
57
|
Advanced seminoma and nonseminoma: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009.
|
Urology
|
2011
|
0.80
|
|
58
|
Taxanes: still a major weapon in the armamentarium against prostate cancer.
|
Eur Urol
|
2013
|
0.80
|
|
59
|
Surgical outcomes in patients with primary mediastinal non-seminomatous germ cell tumours and elevated post-chemotherapy serum tumour markers.
|
Eur J Cardiothorac Surg
|
2012
|
0.79
|
|
60
|
Reflex sympathetic dystrophy in patients with metastatic renal cell carcinoma treated with everolimus.
|
Invest New Drugs
|
2009
|
0.78
|
|
61
|
A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma.
|
Urol Oncol
|
2011
|
0.78
|
|
62
|
[Screening and early diagnosis of other cancers (non-small cell lung carcinoma, urologic cancers, liver cancer and melanoma)].
|
Rev Prat
|
2010
|
0.78
|
|
63
|
Bladder-conserving surgery and interstitial brachytherapy for lymph node negative transitional cell carcinoma of the urinary bladder: results of a 28-year single institution experience.
|
Radiother Oncol
|
2004
|
0.77
|
|
64
|
[Locally advanced prostate cancer: definition, prognosis and treatment].
|
Bull Cancer
|
2007
|
0.77
|
|
65
|
Towards random sequencing or precision medicine in castration-resistant prostate cancer?
|
Eur Urol
|
2013
|
0.76
|
|
66
|
Rebuttal from authors re: Joaquim Bellmunt. Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail? Eur Urol 2009;55:1310-2.
|
Eur Urol
|
2008
|
0.75
|
|
67
|
Who should receive androgen deprivation therapy?
|
Eur Urol
|
2012
|
0.75
|
|
68
|
Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown primary).
|
BMC Cancer
|
2007
|
0.75
|
|
69
|
Expanding horizons in metastatic prostate cancer treatment.
|
Nat Rev Clin Oncol
|
2011
|
0.75
|
|
70
|
Combining docetaxel with estramustine: back to the future?
|
J Clin Oncol
|
2009
|
0.75
|
|
71
|
Natural history of patients presenting biochemical recurrence after radical prostatectomy: some good news?
|
Eur Urol
|
2011
|
0.75
|
|
72
|
Can a cure be achieved with taxane-based chemotherapy plus surgery in patients with primary mediastinal non-seminomatous germ cell tumors and progression or relapse despite first-line chemotherapy?
|
Onkologie
|
2010
|
0.75
|
|
73
|
[Management of clinical stage I testicular germ cell tumours].
|
Bull Cancer
|
2007
|
0.75
|
|
74
|
Familial primary mediastinal nonseminomatous germ-cell tumors.
|
Urol Oncol
|
2004
|
0.75
|
|
75
|
Abiraterone in Metastatic Prostate Cancer.
|
N Engl J Med
|
2017
|
0.75
|
|
76
|
[Prostate tumors].
|
Rev Prat
|
2010
|
0.75
|
|
77
|
Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers.
|
Anticancer Drugs
|
2006
|
0.75
|
|
78
|
[Management of localized germ-cell tumours of the testis].
|
Rev Prat
|
2007
|
0.75
|
|
79
|
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology?
|
Curr Opin Urol
|
2017
|
0.75
|
|
80
|
False positive 2-(18)Fluroro-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with disseminated seminoma and post-chemotherapy residual masses.
|
Clin Genitourin Cancer
|
2012
|
0.75
|
|
81
|
[High dose chemotherapy and germ cell tumor].
|
Bull Cancer
|
2011
|
0.75
|
|
82
|
[Clinical practice guidelines: Standards, Options and Recommendations for the diagnosis of carcinomas of unknown primary site].
|
Bull Cancer
|
2003
|
0.75
|